Patents Assigned to Targacept, Inc.
-
Patent number: 9532974Abstract: The present invention relates to compounds that modulate nicotinic receptors as non-competitive antagonists, methods for their synthesis, methods for use, and their pharmaceutical compositions.Type: GrantFiled: August 27, 2015Date of Patent: January 3, 2017Assignee: Targacept, Inc.Inventors: Srinivasa Rao Akireddy, Balwinder Singh Bhatti, Ronald Joseph Heemstra, Matt S. Melvin, Jason Speake, Yunde Xiao, Daniel Yohannes
-
Patent number: 9145396Abstract: The present invention relates to the stereospecific synthesis of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine, its salt forms, and novel polymorphic forms of these salts.Type: GrantFiled: November 7, 2013Date of Patent: September 29, 2015Assignee: Targacept, Inc.Inventors: Srinivasa Rao Akireddy, Balwinder Singh Bhatti, Timothy J. Cuthbertson, Gary Maurice Dull, Craig Harrison Miller, Joseph Pike Mitchener, Julio A. Munoz, Pieter Albert Otten
-
Patent number: 9107915Abstract: Patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, are treated by administering to a patient in need thereof compositions that are hydroxybenzoate salts of E-metanicotine-type compounds. The formation of hydroxybenzoate salts of the E-metanicotine compounds is also useful in purifying the E-metanicotine compounds, as the hydroxybenzoate salts tend to crystallize out, leaving impurities such as Z-metanicotine compounds, and compounds where the double bond has migrated, in solution. If desired, the hydroxybenzoate salts can be converted to either the free base (the E-metanicotine compound) or to another pharmaceutically acceptable salt form.Type: GrantFiled: June 5, 2014Date of Patent: August 18, 2015Assignee: Targacept, Inc.Inventors: Julio A. Munoz, John Genus, James R. Moore
-
Patent number: 8921410Abstract: Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are amide compounds which can be prepared from certain heteroaryl carboxylic acids and certain diazabicycloalkanes. The compounds exhibit selectivity for, and bind with high affinity to, neuronal nicotinic receptors of the ?4?2 subtype in the central nervous system (CNS). The compounds and compositions can be used to treat and/or prevent a wide variety of conditions or disorders, particularly CNS disorders. The compounds can: (i) alter the number of nicotinic cholinergic receptors of the brain of the patient, (ii) exhibit neuroprotective effects, and (iii) when employed in effective amounts, not result in appreciable adverse side effects (e.g. side effects such as significant increases in blood pressure and heart rate, significant negative effects upon the gastrointestinal tract, and significant effects upon skeletal muscle).Type: GrantFiled: July 23, 2012Date of Patent: December 30, 2014Assignee: Targacept, Inc.Inventors: Anatoly Mazurov, Lan Miao, Yunde Xiao
-
Patent number: 8901151Abstract: The present invention relates to compounds that bind to and modulate the activity of neuronal nicotinic acetylcholine receptors, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central nervous system (CNS).Type: GrantFiled: May 14, 2013Date of Patent: December 2, 2014Assignee: Targacept, Inc.Inventors: Merouane Bencherif, Nikolai Fedorov, Terry Hauser, Kristen Jordan, Sharon Rae Letchworth, Anatoly Mazurov, Julio A. Munoz, Jason Speake, Daniel Yohannes
-
Patent number: 8901177Abstract: The present invention relates to dexmecamylamine and the use of dexmecamylamine, substantially free of exo-R-mecamylamine, in the treatment of bladder disorders, including overactive bladder.Type: GrantFiled: March 13, 2013Date of Patent: December 2, 2014Assignee: Targacept, Inc.Inventors: Merouane Bencherif, Steven M. Toler
-
Patent number: 8859609Abstract: Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are amide compounds which can be prepared from certain heteroaryl carboxylic acids and certain diazabicycloalkanes. The compounds exhibit selectivity for, and bind with high affinity to, neuronal nicotinic receptors of the ?4?2 subtype in the central nervous system (CNS). The compounds and compositions can be used to treat and/or prevent a wide variety of conditions or disorders, particularly CNS disorders. The compounds can: (i) alter the number of nicotinic cholinergic receptors of the brain of the patient, (ii) exhibit neuroprotective effects, and (iii) when employed in effective amounts, not result in appreciable adverse side effects (e.g. side effects such as significant increases in blood pressure and heart rate, significant negative effects upon the gastrointestinal tract, and significant effects upon skeletal muscle).Type: GrantFiled: January 3, 2012Date of Patent: October 14, 2014Assignee: Targacept, Inc.Inventors: Anatoly Mazurov, Lan Miao, Yunde Xiao
-
Patent number: 8846715Abstract: The present invention relates to (2S,3R)—N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms thereof, methods for its preparation, novel intermediates, and methods for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central and autonomic nervous systems.Type: GrantFiled: July 22, 2013Date of Patent: September 30, 2014Assignee: Targacept, Inc.Inventors: Merouane Bencherif, Lisa Benson, Gary Maurice Dull, Nikolai Federov, Gregory J. Gatto, Kristen G. Jordan, Anatoly A. Mazurov, Lan Miao, Julio A. Munoz, Inigo Pfeiffer, Sondra Pfeiffer, Teresa Phillips
-
Publication number: 20140288169Abstract: The present invention relates to compounds that modulate nicotinic receptors as non-competitive antagonists, methods for their synthesis, methods for their use, and their pharmaceutical compositions.Type: ApplicationFiled: January 5, 2012Publication date: September 25, 2014Applicant: TARGACEPT, INC.Inventors: Srinivasa Rao Akireddy, Scott R. Breining, Matt S. Melvin, Srinivasa V. Murthy, Anatoly A. Mazurov, Balwinder Singh Bhatti, Jon-Paul Strachan, Ronald Joseph Heemstra, Todd Showalter, Yunde Xiao, Philip S. Hammond, Lan Miao, David Kombo, Daniel Yohannes, Jason Speake
-
Publication number: 20140249141Abstract: The present invention relates to compounds that bind to and modulate the activity of neuronal nicotinic acetylcholine receptors, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders, including inflammatory diseases and diseases associated with dysfunction of the central nervous system (CNS).Type: ApplicationFiled: August 20, 2012Publication date: September 4, 2014Applicant: Targacept, Inc.Inventors: Anatoly Mazurov, Lan Miao, Todd Showalter
-
Publication number: 20140234270Abstract: The present invention includes methods, uses, and selective alpha7 nAChR ligands for treating or preventing disease and disorders in which stimulation of neurogenesis is ameliorative; namely, wherein the recruitment of neurogenesis is therapeutic.Type: ApplicationFiled: April 23, 2014Publication date: August 21, 2014Applicant: TARGACEPT, INC.Inventors: Merouane Bencherif, Kristen Jordan, Terry Hauser, Steven M. Toler, Sharon Rae Letchworth, David C. Kombo
-
Patent number: 8809397Abstract: The present invention relates to compounds that modulate nicotinic receptors as non-competitive antagonists, methods for their synthesis, methods for use, and their pharmaceutical compositions.Type: GrantFiled: May 24, 2011Date of Patent: August 19, 2014Assignee: Targacept, Inc.Inventors: Srinivasa Rao Akireddy, Balwinder Singh Bhatti, Ronald Joseph Heemstra, Matt S. Melvin, Jason D. Speake, Yunde Xiao, Daniel Yohannes
-
Patent number: 8802694Abstract: The present invention relates to compounds that bind to and modulate the activity of neuronal nicotinic acetylcholine receptors, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central nervous system (CNS).Type: GrantFiled: December 3, 2010Date of Patent: August 12, 2014Assignee: Targacept, Inc.Inventors: Srinivasa Rao Akireddy, Balwinder Singh Bhatti, Ronald Joseph Heemstra, Srinivasa V. Murthy, Jon-Paul Strachan, Yunde Xiao
-
Patent number: 8778978Abstract: Patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, are treated by administering to a patient in need thereof compositions that are hydroxybenzoate salts of E-metanicotine-type compounds. The formation of hydroxybenzoate salts of the E-metanicotine compounds is also useful in purifying the E-metanicotine compounds, as the hydroxybenzoate salts tend to crystallize out, leaving impurities such as Z-metanicotine compounds, and compounds where the double bond has migrated, in solution. If desired, the hydroxybenzoate salts can be converted to either the free base (the E-metanicotine) or to another pharmaceutically acceptable salt form.Type: GrantFiled: October 3, 2013Date of Patent: July 15, 2014Assignee: Targacept, Inc.Inventors: Julio A. Munoz, John Genus, James R. Moore
-
Publication number: 20140194525Abstract: A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition.Type: ApplicationFiled: March 12, 2014Publication date: July 10, 2014Applicant: Targacept, Inc.Inventors: Douglas Shytle, Paul Sanberg, Mary Newman, Archie A. Silver
-
Publication number: 20140163065Abstract: The present invention relates to compounds that bind to and modulate the activity of neuronal nicotinic acetylcholine receptors, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central nervous system (CNS).Type: ApplicationFiled: May 14, 2013Publication date: June 12, 2014Applicant: TARGACEPT, INC.Inventors: Merouane Bencherif, Nikolai Fedorov, Terry Hauser, Kristen Jordan, Sharon Rae Letchworth, Anatoly Mazurov, Julio A. Munoz, Jason Speake, Daniel Yohannes
-
Patent number: 8703802Abstract: An improved process for the preparation of aryl substituted olefinic amines such as (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine and (2S)-(4E)-N-methyl-5-[3-(5-methoxypyridin)yl]-4-penten-2-amine and new intermediates used in said process.Type: GrantFiled: May 19, 2011Date of Patent: April 22, 2014Assignee: Targacept, Inc.Inventors: Gary Maurice Dull, John Genus, Tommi Ratilainen, Per Olof Ryberg, Janna Hellström, Niklas Wahlström, Thomas Wännman
-
Publication number: 20140107164Abstract: Novel vinylazacycloalkane compounds of Formula (I) are disclosed. The compounds are ligands of various nAChRs. The compounds and their pharmaceutically acceptable salts can be used to prepare pharmaceutical compositions and/or medicaments intended to prevent or treat disorders associated with dysfunction of nAChRs, especially within the central nervous system or the gastrointestinal system. Examples of types of disorders that can be treated include neurodegenerative disorders, including central nervous system disorders such as Alzheimer's disease, cognitive disorders, motor disorders such as Parkinson's disease, drug addiction, behavioral disorders and inflammatory disorders within the gastrointestinal system. The compounds can also serve as analgesics in the treatment of acute, chronic or recurrent pain.Type: ApplicationFiled: December 17, 2013Publication date: April 17, 2014Applicant: Targacept, Inc.Inventors: Jeffrey Daniel Schmitt, Gary Maurice Dull, Arielle Genevois-Borella, Marc Capet, Michel Cheve, Craig Harrison Miller
-
Publication number: 20140066460Abstract: The present invention relates to the stereospecific synthesis of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine, its salt forms, and novel polymorphic forms of these salts.Type: ApplicationFiled: November 7, 2013Publication date: March 6, 2014Applicant: Targacept, Inc.Inventors: Srinivasa Rao Akireddy, Balwinder Singh Bhatti, Timothy J. Cuthbertson, Gary Maurice Dull, Craig Harrison Miller, Joseph Pike Mitchener, Julio A. Munoz, Pieter Albert Otten
-
Publication number: 20140039014Abstract: Patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, are treated by administering to a patient in need thereof compositions that are hydroxybenzoate salts of E-metanicotine-type compounds. The formation of hydroxybenzoate salts of the E-metanicotine compounds is also useful in purifying the E-metanicotine compounds, as the hydroxybenzoate salts tend to crystallize out, leaving impurities such as Z-metanicotine compounds, and compounds where the double bond has migrated, in solution. If desired, the hydroxybenzoate salts can be converted to either the free base (the E-metanicotine) or to another pharmaceutically acceptable salt form.Type: ApplicationFiled: October 3, 2013Publication date: February 6, 2014Applicant: Targacept, Inc.Inventors: Julio A. Munoz, John Genus, James R. Moore